It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The incidence of Alzheimer’s Disease in females is almost double that of males. To search for sex-specific gene associations, we build a machine learning approach focused on functionally impactful coding variants. This method can detect differences between sequenced cases and controls in small cohorts. In the Alzheimer’s Disease Sequencing Project with mixed sexes, this approach identified genes enriched for immune response pathways. After sex-separation, genes become specifically enriched for stress-response pathways in male and cell-cycle pathways in female. These genes improve disease risk prediction in silico and modulate Drosophila neurodegeneration in vivo. Thus, a general approach for machine learning on functionally impactful variants can uncover sex-specific candidates towards diagnostic biomarkers and therapeutic targets.
More females than males suffer from Alzheimer’s Disease for reasons not well understood. Here, using a novel machine learning approach focused on functionally impactful coding variants, the authors identify potential sex-specific modulators of neurodegeneration.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Baylor College of Medicine, Department of Molecular and Human Genetics, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)
2 Baylor College of Medicine, Department of Molecular and Human Genetics, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X); Texas Children’s Hospital, Jan and Dan Duncan Neurological Research Institute, Houston, USA (GRID:grid.416975.8) (ISNI:0000 0001 2200 2638); Baylor College of Medicine, Center for Alzheimer’s and Neurodegenerative Diseases, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)
3 Baylor College of Medicine, Department of Molecular and Human Genetics, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X); UTHealth McGovern Medical School, Department of Biology and Pharmacology, Houston, USA (GRID:grid.39382.33)
4 Baylor College of Medicine, Department of Molecular and Human Genetics, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X); Baylor College of Medicine, Center for Alzheimer’s and Neurodegenerative Diseases, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X); Baylor College of Medicine, Computational and Integrative Biomedical Research Center, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X)